TOT BIOPHARM International Company Company Description

TOT BIOPHARM International Company Limited, an investment holding company, engages in the research and development, manufacturing, and marketing of anti-tumor drugs in Mainland China and internationally.

The company offers Pusintin, a bevacizumab injection to treat advanced, metastatic or recurrent non-squamous non-small cell lung cancer; metastatic colorectal cancer; recurrent glioblastoma multiforme; epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer; and cervical cancer.

It also provides Tazian, a temozolomide capsule for the treatment of newly diagnosed glioblastoma multiforme or anaplastic astrocytoma that recurs or progresses after conventional treatment.

In addition, the company develops TAB014 that has completed Phase III clinical trial for the treatment of wet age-related macular degeneration (wAMD); TAE020, which is in preclinical trial to treat acute myeloid leukemia; and TAC020, which is in preclinical trial for the treatment of various solid tumors.

Further, it is involved in contract development and manufacturing organization (CDMO)/contract manufacture organization (CMO) business; and license-out of self-developed biological drugs.

TOT BIOPHARM International Company Limited was incorporated in 2009 and is headquartered in Suzhou, China.

TOT BIOPHARM International Company Limited

Country	Hong Kong
Founded	2009
Industry	Biotechnology
Sector	Healthcare
Employees	611
CEO	Jun Liu

Contact Details

Address: No. 120 Changyang Street Suzhou, 215024 China
Phone	86 512 6296 5186
Website	totbiopharm.com.cn

Stock Details

Ticker Symbol	1875
Exchange	Hong Kong Stock Exchange
Fiscal Year	January - December
Reporting Currency	CNY
ISIN Number	HK0000545266
SIC Code	2836

Key Executives

Name	Position
Dr. Jun Liu	Chief Executive Officer, Chief Scientific Officer and Executive Director
Ben Xiao	Group Vice President of Finance and Investor Relations
Wing Yat Lui	Joint Company Secretary
Yifan Chen	Joint Company Secretary